ACTG

ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication

Retrieved on: 
Wednesday, March 6, 2024

“ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Key Points: 
  • “ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.
  • Participants received incentives and support to adhere to their daily oral medication to first achieve viral suppression and if successful, they were randomized to either receive long-acting injectable treatment every four weeks or continue taking daily oral medication.
  • The long-acting injectable treatment was more effective than the daily oral medication at maintaining virologic suppression and avoiding treatment-related discontinuation.
  • Twenty-eight participants receiving the long-acting injectable treatment experienced regimen failure (defined as virologic failure or treatment discontinuation), compared to 47 receiving daily oral medication.

ACTG CROI Presentation Demonstrates Superiority of HepB-CpG Vaccine Over Conventional Hepatitis B Vaccine Among People Living With HIV Who Have Not Previously Responded to Vaccination

Retrieved on: 
Wednesday, March 6, 2024

These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.

Key Points: 
  • These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.
  • People living with HIV, especially those with lower CD4 counts, often do not develop protective antibodies after receiving conventional hepatitis B vaccines.
  • The HepB-CpG (HEPLISAV-B®) vaccine includes a TLR-9 agonist adjuvant (CpG 1018® adjuvant) and is known to achieve high protection against hepatitis B among people living with HIV, but until now there have been limited data about its protection among people living with HIV who have not responded to conventional hepatitis B vaccines.
  • “Hepatitis B remains a significant issue for people living with HIV, as having both viruses increases the likelihood of liver complications,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Retrieved on: 
Tuesday, March 5, 2024

WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus (HIV), at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.

Key Points: 
  • These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.
  • The study enrolled 52 participants and was conducted by the AIDS Clinical Trials Group (ACTG), a clinical trials network funded by the National Institute of Allergy and Infectious Diseases, NIH.
  • The antibody was safe and well-tolerated at all dose levels and via both intravenous and subcutaneous administration.
  • These clinical data on an HIV multispecific antibody inform the future advancement of such antibodies for the prevention and treatment of HIV and provide strong rationale for the development of current and future antibody products.

ACTG CROI Presentations Show That Semaglutide Improves Metabolic-Associated Steatotic Liver Disease Among People Living With HIV

Retrieved on: 
Tuesday, March 5, 2024

Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.

Key Points: 
  • Yesterday, the SLIM LIVER poster “Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER study” was presented.
  • Together, these presentations demonstrate that semaglutide was highly effective in improving, and in some cases, resolving completely, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease) among people living with HIV.
  • SLIM LIVER is the first study evaluating semaglutide as a treatment for MASLD among people living with HIV.
  • MASLD is common among people living with HIV and likely acts synergistically with HIV to accelerate liver injury and organ dysfunction.

ACTG Presents Study at CROI Elucidating Mechanism of CMV on Aging-Related Pathways in HIV

Retrieved on: 
Monday, March 4, 2024

CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.

Key Points: 
  • CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV.
  • Prior to the availability of effective antiretroviral therapy (ART) for HIV, CMV caused life-threatening infections in the eyes, brain, and gut in people with compromised immune systems due to advanced HIV.
  • “Investigators have found associations between CMV and heart disease, cancer, and other aging-related complications among people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges

Retrieved on: 
Wednesday, March 6, 2024

Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.

Key Points: 
  • Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.
  • Participants received comprehensive and incentivised adherence support while taking guideline-recommended, three-drug regimen oral ART, including dolutegravir and bictegravir-based regimens, to achieve viral suppression.
  • 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC {difference -14.4 (98.75% CI–29.8%, -0.8%)}.
  • Three participants in the LA-ART arm had serious injection site reactions (ISR) and one participant discontinued due to an ISR.

Acacia Research to Release Fourth Quarter and Full Year 2023 Financial Results on March 14

Retrieved on: 
Thursday, February 29, 2024

Acacia Research Corporation (NASDAQ: ACTG) announced today it will release its fourth quarter and full-year 2023 financial results after the market closes on Thursday, March 14, 2024.

Key Points: 
  • Acacia Research Corporation (NASDAQ: ACTG) announced today it will release its fourth quarter and full-year 2023 financial results after the market closes on Thursday, March 14, 2024.
  • The Company will host a conference call on the same day to discuss these results at 4:30 p.m. ET/ 1:30 p.m. PT.
  • To access the live call, please dial 888-506-0062 (U.S. and Canada) or 973-528-0011 (international) and if requested, reference conference ID 248690.
  • Following the conclusion of the live call, a replay of the webcast will be available on the Company's website for at least 30 days.

Acacia Research Expands Oil and Gas Investments Through Benchmark Energy’s Transformative Acquisition in the Western Anadarko Basin

Retrieved on: 
Tuesday, February 20, 2024

The Acquisition is anticipated to expand the Benchmark portfolio, adding approximately 140,000 net acres and approximately 470 operated producing wells in the prolific Western Anadarko Basin throughout the Texas Panhandle and Western Oklahoma.

Key Points: 
  • The Acquisition is anticipated to expand the Benchmark portfolio, adding approximately 140,000 net acres and approximately 470 operated producing wells in the prolific Western Anadarko Basin throughout the Texas Panhandle and Western Oklahoma.
  • Kirk Goehring, Benchmark’s Chief Executive Officer, commented: “The acquisition of these assets represents a transformative moment in Benchmark Energy’s history and an important next step in our partnership with Acacia and McArron.
  • Further, the Assets’ proximity to Benchmark’s existing operations in Texas creates further potential to develop operational synergies of scale in the basin.
  • Additional details about the acquisition are included in a Form 8-K filed by Acacia today with the Securities and Exchange Commission.

ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis Regimen Among People Living with HIV

Retrieved on: 
Wednesday, February 14, 2024

Previously, ACTG study A5349 demonstrated that a four-month, four-drug TB regimen that included high-dose rifapentine was as effective as the standard six-month regimen, cutting the treatment time by one third.

Key Points: 
  • Previously, ACTG study A5349 demonstrated that a four-month, four-drug TB regimen that included high-dose rifapentine was as effective as the standard six-month regimen, cutting the treatment time by one third.
  • “Understanding the relationship between these anti-TB and HIV medications is crucial, as an estimated one third of people living with HIV worldwide are at risk for developing TB,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles.
  • Dolutegravir is being supplied to study A5406 by ViiV Healthcare Ltd and the fixed-dose combination of dolutegravir/tenofovir disoproxil fumarate/lamivudine is being supplied by Viatris.
  • The ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice Chair).

Acacia Research Appoints Martin (“MJ”) D. McNulty, Jr. to Board of Directors, Named Permanent CEO

Retrieved on: 
Wednesday, February 14, 2024

Acacia Research Corporation (Nasdaq: ACTG) today announced that Martin (“MJ”) D. McNulty, Jr. has been named as Acacia’s permanent Chief Executive Officer.

Key Points: 
  • Acacia Research Corporation (Nasdaq: ACTG) today announced that Martin (“MJ”) D. McNulty, Jr. has been named as Acacia’s permanent Chief Executive Officer.
  • Mr. McNulty has been serving as the Company’s Interim Chief Executive Officer since November 1, 2022.
  • In addition, the Board of Directors expanded the size of the Board from six to seven directors, and the Board appointed Mr. McNulty as a director of the Company to serve until the Company’s 2024 annual meeting of stockholders.
  • The Board is confident that MJ possesses the unique skillset, leadership and strategic vision to lead Acacia forward.